Pharmnovo
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Scheeletorget 1, Lund, Skaane, SE-223 81...Phone Number
+46709131008Website
www.pharmnovo.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Pharmnovo
Pharmnovo is a clinical phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. The company conducts pharmaceutical research and clinical development to evaluate the safety and effectiveness of its therapies. Its research platform may also support potential applications in areas such as migraine, anxiety, depression, and chronic cough. PharmNovo’s mission is to develop safer and more effective medicines for people suffering from chronic pain.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Pharmnovo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Pharmnovo, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Pharmnovo has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Pharmnovo has new funding data
Click to see if Pharmnovo had a recent Job posting/layoffs
Check out if Pharmnovo is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Pharmnovo
Product Launch: Get notified when Pharmnovo launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Pharmnovo recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Pharmnovo as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Pharmnovo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Pharmnovo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Pharmnovo.
Pharmnovo financials insights
Gather financial insights about Pharmnovo, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$6.4M
2024
Private Equity
$16.5M
Grant
$2.8M
2026
Other Financing Round
$4.1M
Pharmnovo Tech Stack
A closer look at the technologies used by Pharmnovo
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Funding
Left Company
Executive Move
New Hire
Executive Move
Pharmnovo News & Media
PharmNovo awarded blended funding of €17.5M from EIC for innovative pain treatment
PharmNovo, a Swedish clinical-stage pharmaceutical company, has been awarded €17.5 M in blended funding from the European Innovation Council (EIC) Accelerator under the Horizon Europe program. The funding consists of a grant of €2.5 million and equity investments through the EIC Fund of up to €15 million, contingent upon securing equivalent funding from co-investors. Jesper Kjerulff, COO and Project Lead of PharmNovo, stated: “This funding will support PharmNovo to advance PN6047 through a PhasePharmNovo announces positive Phase I results for neuropathic pain management drug PN6047
Swedish pharmaceutical company PharmNovo is proud to announce the positive final results from the Phase I trial of its neuropathic pain drug candidate, PN6047. This trial demonstrates the safety and tolerability of PN6047, underscoring its potential as an innovative option in pain management. PharmNovo, a clinical-stage pharmaceutical company, focuses on the development of safe and effective treatments for neuropathic pain. The findings from the Phase I trial show that PN6047 is safe and well-toNIDA funds studies on PN6047 from PharmNovo for potential opioid withdrawal treatment
The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047 from PharmNovo as a potential treatment for opioid withdrawal syndrome. PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge. The persistent challenge of opioid addiction, involving substances such as heroin, fentanyl, and oxycodone, remains a significant public health concern both in the United StatesPharmNovo signs agreement with Worldwide Clinical Trials for phase IIa study of PN6047 in neuropathic pain
PharmNovo, a Swedish pharmaceutical company developing neuropathic pain treatments, announces its collaboration with Worldwide Clinical Trials, a full-service contract research organisation (CRO), to conduct the phase IIa study of PN6047.The study is planned to start in 2024. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Al
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Pharmnovo
Sign Up For FreeTo access detailed company insights
Pharmnovo is a clinical phase pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. The company conducts pharmaceutical research and clinical development to evaluate the safety and effectiveness of its therapies. Its research platform may also support potential applications in areas such as migraine, anxiety, d... Read More
